Reports

Lululemon delivered robust fourth-quarter performance in fiscal 2024, with revenue rising 13% year-over-year to $3.61 billion and EPS reaching $6.14. The company achieved gains across geographies, especially internationally, and reported record gross and operating margins.

• Q4 revenue grew 13% YoY to $3.61 billion.
• Diluted EPS rose to $6.14 from $5.29 in Q4 2023.

TD SYNNEX delivered strong Q1 FY25 results with $14.53 billion in revenue and $2.80 in non-GAAP EPS. Despite challenges from a higher net revenue presentation, the company demonstrated solid performance with broad-based growth in gross billings and improved margins in the Americas.

• Revenue rose 4.0% year-over-year to $14.53 billion.
• Non-GAAP EPS was $2.80, within guidance.

RH delivered strong Q4 performance with revenue growth, improved margins, and a significant increase in adjusted operating income, despite ongoing challenges in the housing market.

• Revenue rose to $812M, up from $738M last year.
• Adjusted operating income increased 38% YoY.

Braze delivered a robust performance in Q4 FY25, achieving 22.5% year-over-year revenue growth and turning profitable on a non-GAAP basis. Strong subscription revenue and improved operating efficiency contributed to positive free cash flow and margin expansion.

• Revenue grew 22.5% year-over-year to $160,400,000.
• Non-GAAP EPS turned positive to $0.12 from a loss of $0.04 a year ago.

In Q3 FY2025, AAR Corp achieved $678.2 million in sales, a 20% year-over-year increase, driven by strong growth across its segments. Despite a GAAP net loss due to a divestiture charge, adjusted EPS rose 16% to $0.99, and margins improved significantly, reflecting operational efficiencies and contributions from recent acquisitions.

• Sales increased 20% year-over-year to $678.2 million.
• Adjusted EPS rose 16% to $0.99, while GAAP EPS was -$0.25 due to divestiture charges.

Argan, Inc. reported a 41% year-over-year increase in revenue for Q4 2024, driven by active construction across key energy infrastructure projects. The company achieved record net income and EPS, with strong contributions from all business segments.

• Q4 revenue rose 41% YoY to $232.5 million.
• Gross margin improved to 20.5% from 14.4% YoY.

Winnebago generated $620.2 million in revenue for Q2 2025, down 11.8% from the prior year. The company posted a net loss of $0.4 million and operating income of $7.8 million. Adjusted EPS was $0.19, down from $0.93 a year earlier, and adjusted EBITDA declined over 54%. Segment performance varied, with Marine revenue rising but Motorhome sales falling significantly.

• Revenue declined 11.8% YoY to $620.2 million in Q2 2025.
• Net loss was $0.4 million, a major improvement from $12.7 million loss last year.

Harrow delivered a record $66.8 million in revenue for Q4 2024, marking an 84% increase over the prior-year period. The company reported $6.78 million in GAAP net income, with EPS of $0.19 basic and $0.24 diluted. Adjusted EBITDA reached $22.5 million, highlighting the company's profitability and operational leverage.

• Total revenue for Q4 2024 reached $66.8 million, up 84% from Q4 2023.
• GAAP net income was $6.78 million for the quarter.

In Q4 2024, Pulse Biosciences posted a GAAP net loss of $19.4 million and a non-GAAP net loss of $10.4 million. The company had no revenue, and costs rose due to expansion activities and stock-based compensation. The company ended the quarter with strong liquidity following a successful warrant exercise.

• No revenue was reported for Q4 2024.
• GAAP net loss widened to $19.4 million from $11.9 million YoY.

Bitfarms generated $56 million in revenue during Q4 2024, up 21% year-over-year. Despite a $16 million operating loss, the company posted a net income of $15 million, marking a significant turnaround from a $62 million loss in Q4 2023. Adjusted EBITDA was $14.3 million, and gross mining margin declined to 47%.

• Revenue rose 21% year-over-year to $56 million in Q4 2024.
• Net income reached $15 million compared to a $62 million net loss in Q4 2023.

Arbutus Biopharma reported Q4 2024 revenue of $1.57 million and an EPS loss of -$0.07, outperforming expectations slightly. The company continued to manage its cash position effectively, with $122.62 million in cash, cash equivalents, and investments. Key developments included pipeline evaluations and corporate restructuring.

• Revenue for Q4 2024 was $1.57 million, down 26.71% year-over-year.
• EPS loss of -$0.07 beat analyst expectations by $0.01.

Immunome reported a net loss of $292.963 million for the full year ended December 31, 2024. The company's cash, cash equivalents, and marketable securities totaled $217.3 million as of December 31, 2024, and its cash runway is expected to extend into 2027. Key pipeline updates include topline data for the Phase 3 RINGSIDE study of varegacestat expected in the second half of 2025, the first patient dosed in the Phase 1 clinical trial for IM-1021, and an IND submission for IM-3050.

• Topline data for Phase 3 RINGSIDE study of varegacestat in progressing desmoid tumors expected in second half of 2025.
• First patient dosed in Phase 1 clinical trial evaluating IM-1021, a ROR1-targeted ADC.

In Q4 2024, Tsakos Energy Navigation (TEN) generated $188.26 million in revenue and reported $0.42 in EPS. Net income attributable to common stockholders was $12.52 million, and adjusted EBITDA came in at $85.56 million. The company managed lower fleet utilization due to drydockings but continued to control costs and maintain a healthy balance sheet.

• Q4 revenue reached $188.26 million, down from $220.24 million a year ago.
• EPS for the quarter was $0.42, beating expectations by $0.02.

In Q4 2024, Savara posted a net loss of $29.04 million or $(0.13) per share, primarily due to increased investment in research and development and commercial preparation for MOLBREEVI. The company ended the quarter with strong liquidity, holding $196.33 million in cash and short-term investments.

• Net loss widened to $29.04 million from $16.1 million in Q4 2023.
• EPS came in at $(0.13), down from $(0.09) a year earlier.

In Q4 2024, Gevo posted $8.9 million in combined operating revenue and investment income and ended the quarter with $259 million in cash, cash equivalents, and restricted cash. The company reported a net loss per share of $0.08, an operating loss of $19.6 million, and an adjusted EBITDA loss of $11.3 million. Its RNG subsidiary posted a modest adjusted EBITDA profit despite a loss from operations.

• Q4 2024 combined revenue and investment income reached $8.9 million.
• Gevo ended the quarter with $259 million in cash, cash equivalents, and restricted cash.

In Q4 2024, YXT.com experienced a challenging quarter, with revenue dropping to $10.9M and net loss expanding to $10.5M. The company emphasized AI-driven transformation and cost controls, but the topline and adjusted earnings still declined significantly.

• Q4 revenue was $10.9M, down from $13.0M in Q4 2023.
• Net loss widened to $10.5M in Q4, compared to just $2.1M in the first nine months combined.

In Q4 2024, Third Harmonic Bio recorded no revenue and a net loss of $13.1 million or -$0.29 per share. The increase in expenses was driven by continued investment in the THB335 program. The company ended the quarter with $285.1 million in cash and cash equivalents and continues its strategic review process.

• EPS was -$0.29, improving on expectations by $0.04.
• Q4 net loss increased to $13.1 million from $6.8 million in Q4 2023.

Acumen posted a $37.1M net loss in Q4 2024, driven by increased R&D spending on its ALTITUDE-AD trial. The company did not generate revenue and remains focused on its Alzheimer’s pipeline.

• Net loss reached $37.1M in Q4 with no revenue generated.
• R&D expenses surged to $27.2M due to the ongoing Phase 2 trial.

Urban One posted a net loss of $35.7 million in Q4 2024, driven by an operating loss of $1.9 million and a 2.7% drop in revenue. Adjusted EBITDA remained stable year-over-year, and cash reserves stood at $137.1 million by year-end.

• Revenue declined by 2.7% YoY to $117.1 million in Q4 2024.
• Net loss widened to $35.7 million, compared to $11.0 million in Q4 2023.

Sachem Capital ended Q4 2024 with a significant net loss of $37.3 million as revenue declined and credit loss provisions surged. Loan originations remained weak, impacting interest and fee income.

• Revenue for Q4 2024 was $10.4 million, the lowest of the year.
• Net loss attributable to common shareholders reached $37.3 million in Q4.

In Q4 2024, Shattuck Labs reported no revenue and a net loss of $18.68 million, or -$0.37 per share. Operating expenses remained stable, with R&D and G&A expenses similar to the previous year. The company held $73 million in cash and investments at quarter-end, expected to fund operations into 2027.

• Net loss for Q4 2024 was $18.68 million, or -$0.37 per share.
• R&D expenses were $15.4 million, nearly unchanged from the prior year.

PDS Biotechnology reported a net loss of $37.6 million for the full year ended December 31, 2024, a reduction from the $42.9 million net loss in the prior year. This improvement was primarily driven by decreased operating expenses, partially offset by increased net interest expense. The company also initiated a pivotal Phase 3 clinical trial for Versamune® HPV in HPV16-positive head and neck cancer.

• Net loss for the full year 2024 decreased to $37.6 million from $42.9 million in 2023.
• Research and development expenses decreased by $5.2 million to $22.6 million in 2024.

Atara Biotherapeutics reported a net loss of $12.7 million for Q4 2024, a significant improvement from the $60.5 million loss in Q4 2023. Total revenue for the quarter was $32.753 million, primarily driven by commercialization revenue. The company is focusing on EBVALLO and has paused its CAR-T programs.

• Net loss for Q4 2024 was $12.7 million, compared to $60.5 million in Q4 2023.
• Total revenue for Q4 2024 was $32.753 million, up from $4.252 million in Q4 2023.

SCYNEXIS reported a net loss of $21.3 million for the full year ended December 31, 2024, with total revenue of $3.7 million, a significant decrease from $140.1 million in 2023. The company ended 2024 with $75.1 million in cash, cash equivalents, and investments, projecting a cash runway into Q3 2026.

• SCYNEXIS reported a full-year 2024 net loss of $21.3 million, or $0.44 basic loss per share.
• Total revenue for the full year 2024 was $3.7 million, primarily from license agreement revenue.

In Q4 2024, P3 Health saw revenue grow 7% year-over-year to $370.7 million, while net loss widened to $129.1 million. Medical margin decreased to $7.3 million, with a higher premium deficiency reserve impacting results. The company grew its at-risk membership to nearly 124,000.

• Total revenue reached $370.7 million, a 7% YoY increase.
• Capitated revenue was $367.5 million, up 7% YoY.

BioAtla announced a substantial decrease in net loss for Q4 2024, down to $14.9 million from $26.9 million in Q4 2023, driven by reduced R&D and G&A expenses. The company also highlighted encouraging clinical outcomes across its CAB platform programs and extended its financial runway into 1H 2026 through cost-reduction measures.

• Net loss significantly decreased to $14.9 million in Q4 2024 from $26.9 million in Q4 2023.
• Research and development expenses decreased by $11.1 million in Q4 2024 compared to Q4 2023, primarily due to lower clinical development expenses and program prioritization.

In Q4 2024, Co-Diagnostics generated $149,330 in revenue and posted an adjusted EPS of -$0.36. The company remained pre-commercial with limited product activity and continued development of its diagnostic platform.

• Q4 revenue totaled $149,330, reflecting limited commercial activity.
• Adjusted EPS was -$0.36, consistent with ongoing R&D investments.

In Q4 2024, BioXcel Therapeutics posted $366,000 in revenue from IGALMI, with a net loss of $10.86 million or -$3.57 per share. Both R&D and SG&A expenses were significantly reduced compared to the prior year, contributing to a narrower operating loss. The company ended the quarter with $29.85 million in cash and continues to focus on advancing the SERENITY and TRANQUILITY programs.

• Revenue from IGALMI was $366,000 in Q4 2024, slightly down from the prior year.
• Net loss narrowed to $10.86 million from $22.26 million in Q4 2023.

Direct Digital Holdings saw Q4 2024 revenue fall sharply due to a sell-side disruption, though cost-cutting efforts led to improved operating loss compared to the prior year. The company reported a net loss but noted sequential improvement and strategic initiatives positioning it for recovery.

• Q4 revenue declined 78% year-over-year to $9.1 million.
• Sell-side revenue dropped 92% due to customer suspension, later reinstated.

Bio-key’s Q4 2024 performance reflected a 20% increase in license fee revenue and a meaningful reduction in net loss. The transition away from lower-margin services and hardware sales contributed to a substantial improvement in profitability despite a year-over-year revenue decline.

• Q4 2024 revenue was $1.46 million, down from $1.83 million in Q4 2023.
• License fee revenue rose 77% to $1.02 million in Q4 2024.